Full Access To HCV Drugs Would Save Money Long-Term, Study Finds
This article was originally published in The Pink Sheet Daily
Restricting coverage to the sickest HCV patients saves individual Medicaid programs money in the short-term, a study by ISPOR finds, but increases costs for Medicare in the longer-term.
You may also be interested in...
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.